PHARMACOECONOMIC EVALUATION OF DABIGATRAN VS WARFARIN IN CARDIOVASCULAR EVENTS PREVENTION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION

PHARMACOECONOMIC EVALUATION OF DABIGATRAN VS WARFARIN IN CARDIOVASCULAR EVENTS PREVENTION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION

According to recent guidelines, oral dabigatran etexilate is indicated for stroke and systemic embolism prevention in patients with atrial fibrillation (AF). Aim. Based on the RE-LY study to evaluate the cost-effectiveness of dabigatran etexilate versus warfarin prescribed in “real-world” settings f...

Full description

Saved in:
Bibliographic Details
Main Authors: Yu. B. Belousov, V. Yu. Mareev, I. S. Yavelov, D. Yu. Belousov
Format: Article
Language:English
Published: Столичная издательская компания 2015-12-01
Series:Рациональная фармакотерапия в кардиологии
Subjects:
dabigatran etexelate
warfarin
vitamin k antagonists
atrial fibrillation
pharmacoecomomics
clinic-economic evaluation
cost-effectiveness
markov modeling
Online Access:https://www.rpcardio.online/jour/article/view/397
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.rpcardio.online/jour/article/view/397

Similar Items